Clearside Biomedical Current Ratio 2015-2021 | CLSD

Clearside Biomedical current ratio from 2015 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Clearside Biomedical Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.03B $0.01B 3.14
2021-03-31 $0.03B $0.01B 2.59
2020-12-31 $0.02B $0.01B 1.82
2020-09-30 $0.02B $0.01B 1.95
2020-06-30 $0.02B $0.01B 1.77
2020-03-31 $0.02B $0.01B 1.71
2019-12-31 $0.03B $0.01B 2.31
2019-09-30 $0.02B $0.01B 2.22
2019-06-30 $0.03B $0.01B 3.47
2019-03-31 $0.04B $0.01B 3.04
2018-12-31 $0.04B $0.01B 4.10
2018-09-30 $0.07B $0.02B 4.59
2018-06-30 $0.09B $0.01B 7.93
2018-03-31 $0.10B $0.01B 7.46
2017-12-31 $0.04B $0.01B 2.90
2017-09-30 $0.05B $0.01B 4.57
2017-06-30 $0.07B $0.01B 9.39
2017-03-31 $0.08B $0.01B 11.20
2016-12-31 $0.08B $0.01B 15.59
2016-09-30 $0.06B $0.00B 19.69
2016-06-30 $0.06B $0.01B 8.32
2016-03-31 $0.02B $0.01B 2.18
2015-12-31 $0.02B $0.01B 3.94
2015-09-30 $0.00B 0.00
2015-06-30 $0.00B 0.00
2015-03-31 $0.00B 0.00
2014-12-31 $0.01B $0.00B 3.44
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.340B $0.008B
Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76